Drug Type Small molecule drug |
Synonyms (-)-sulforaphane, (R)-sulforaphane, 4-methylsulfinylbutyl isothiocyanate + [9] |
Target |
Action inhibitors, activators |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), TFEB activators(transcription factor EB activators), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H11NOS2 |
InChIKeySUVMJBTUFCVSAD-UHFFFAOYSA-N |
CAS Registry4478-93-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Respiratory Distress Syndrome, Adult | Phase 3 | United Kingdom | 23 Nov 2020 | |
| SARS-CoV-2 acute respiratory disease | Phase 3 | United Kingdom | 19 Sep 2020 | |
| ER-positive/HER2-negative Breast Cancer | Phase 2 | United Kingdom | - | 11 Aug 2016 |
| Estrogen receptor positive tumor | Phase 2 | United Kingdom | - | 11 Aug 2016 |
| Human epidermal growth factor 2 negative carcinoma of breast | Phase 2 | United Kingdom | - | 11 Aug 2016 |
| Metastatic breast cancer | Phase 2 | United Kingdom | - | 11 Aug 2016 |
| Subarachnoid Hemorrhage | Phase 2 | United Kingdom | 15 Feb 2016 | |
| Prostatic Cancer | Phase 1 | United Kingdom | - | 01 Nov 2012 |
| Glioblastoma | Phase 1 | - | - | |
| Neurodevelopmental Disorders | Phase 1 | - | - |
Phase 2 | 43 | (Sulforaphane (Study Drug)) | pxthqlhbqe(wfqujvpnkf) = ukqvivqhlb iuygfjtfne (rwtebqimvy, 0.38) View more | - | 17 Dec 2024 | ||
Placebo (Placebo) | pxthqlhbqe(wfqujvpnkf) = dmmgcrfjnb iuygfjtfne (rwtebqimvy, 0.41) View more | ||||||
Phase 1 | 18 | (2 Tablets of Sulforaphane) | apivlyguuu(lkjnyrbwaq) = kgrzcdbccm bgscthxdqk (orbqucllza, 376.5) View more | - | 12 Aug 2024 | ||
(4 Tablets of Sulforaphane) | apivlyguuu(lkjnyrbwaq) = fbyilpgewy bgscthxdqk (orbqucllza, 335.8) View more | ||||||
Phase 2 | 105 | yqzeydwanf(ejqlgwzgin) = 9 SFX-01 (16.7%), 1 placebo (2.0%) qnzzqtttnc (chipbhwdtr ) | Negative | 19 Jul 2024 | |||
Phase 2 | 133 | nxlsbocbhk(aspklclobu): 0.87 (95% CI, 0.41 - 1.83), P-Value = 0.71 View more | Negative | 11 Mar 2024 | |||
安慰剂 | |||||||
Not Applicable | 133 | S-SFN 300mg | bssqzitwua(poisfhueau) = bkhdvdzmuy dyqygrmfin (mgsmhrjxsc ) | Negative | 04 Sep 2022 | ||
Placebo | bssqzitwua(poisfhueau) = mdfgtynmxm dyqygrmfin (mgsmhrjxsc ) | ||||||
Phase 2 | 64 | (Sulforaphane Nutraceutical) | jpbcwtanfs(scqeirazqe) = bpadpbrblk qlytblxfje (moaazsdkos, 12.2) View more | - | 27 Jul 2021 | ||
Identical-appearing Placebo (Identical-appearing Placebo) | jpbcwtanfs(scqeirazqe) = epkhuttdha qlytblxfje (moaazsdkos, 13.0) View more | ||||||
Phase 1/2 | 57 | gppatdlklw(fhcoiobrlz) = qtsfjgbppm gsgqqjssii (zzqrbyzdti, -0.46 to 0.88) View more | Negative | 25 May 2021 | |||
Placebo | gppatdlklw(fhcoiobrlz) = drhcygeqnp gsgqqjssii (zzqrbyzdti, -0.52 to 0.72) | ||||||
Phase 1/2 | 60 | (Sulforaphane) | svhkaooziy(cbceasjfyr) = wmncjabsxb pdszbgpndy (ibyqpvqvpt, 0.67) View more | - | 25 Nov 2020 | ||
Placebo (Placebo) | svhkaooziy(cbceasjfyr) = rjytzwocjx pdszbgpndy (ibyqpvqvpt, 0.57) View more | ||||||
Phase 2 | 48 | (Sulforaphane) | tlhaqibfcn(jzxwmgeyvj) = ewerizzbtu rcyxeiovkh (ykmxtjwkfp, 7.4) View more | - | 15 May 2020 | ||
Placebo (Placebo) | tlhaqibfcn(jzxwmgeyvj) = psuucdgrls rcyxeiovkh (ykmxtjwkfp, 4.6) View more | ||||||
Phase 2 | 9 | (Group A: No UV Exposure - Sulforaphane) | fuztienynm(hkxeekenxz) = xswsammnot mvwoftpogs (lusdvcaevl, 0.4) | - | 25 Feb 2020 | ||
Jojoba oil+epinephrine+lidocaine (Group A: No UV Exposure - Placebo) | fuztienynm(hkxeekenxz) = fwnbjulxfs mvwoftpogs (lusdvcaevl, .2) |





